MedTrace Logo

Glistenings and PCO Evaluation for the Envista MX60

NCT02698943 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-03-04

No results posted yet for this study

Summary

Posterior capsule opacification (PCO) and glistenings development is among the primary reasons for sub-optimal visual capacity following cataract extraction surgery. Primary objective of this study is to evaluate the incidence of PCO and glistenings of the popular envista MX-60 intraocular lens (Bausch + Lomb) in a random sample of cataract patients who underwent phacoemulsification at least 1 year prior to their enrollment at the study

Conditions

  • Cataract

Interventions

PROCEDURE

Phacoemulsification

Phacoemulsification for cataract extraction with Envista MX-60 implantation

Sponsors & Collaborators

  • Democritus University of Thrace

    lead OTHER

Principal Investigators

  • Georgios Labiris, MD, PhD · Assistant Professor

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-02-29
Completion
2016-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02698943 on ClinicalTrials.gov